Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report

Christopoulos P, Herster F, Hoffknecht P, Falk M, Tiemann M, Kopp HG, et al. Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report. Front Oncol 2024 May 06;14:1347742. doi: 10.3389/fonc.2024.1347742

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy- EGFR mutated non-small cell lung cancer IV patients treated with osimertinib

Roeper J, et al. TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy- EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. Transl Lung Cancer Res 2022 Jan;11(1):4-13. doi:10.21037/tlcr-21-754

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer

Scheel AH, et al. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 2018 Feb;72(3):449-459. doi: 10.1111/his.13375

Risk stratification of EGFR + lung cancer diagnosed with panel-based next-generation sequencing

Christopoulos P, et al. Risk stratification of EGFR + lung cancer diagnosed with panel-based next-generation sequencing. Lung Cancer 2020 Oct;148:105-112. doi: 10.1016/j.lungcan.2020.08.007

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

Thunnissen E, et al. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Lung Cancer 2019 Dec;138:13-18. doi: 10.1016/j.lungcan.2019.09.023